The bank upgraded Evotec to overweight from equal weight. It also hiked its price target on U.S.-listed shares to $16 from $12.
You are here: Home / This German drug stock can rally more than 40% thanks to its A.I. potential, Morgan Stanley says
Market News and Views
The bank upgraded Evotec to overweight from equal weight. It also hiked its price target on U.S.-listed shares to $16 from $12.